Clinical Trials Logo
  1. Home
  2. Ineffective Erythropoiesis
  3. NCT04054921

Safety Study for Beta Thalassemia Subjects on PTG-300 — TRANSCEND  

ß-thalassemia Clinical Trial

Official title:
An Open Label Extension Study of PTG-300 In Non-Transfusion Depenent (NTD) and Trasfusion-Dependent (TD) B-Thalassemia Subjects

Clinical Trial Summary

In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.

Clinical Trial Description

The PTG-300-03 study will study beta thalassemia patients on PTG-300 for two years. The dose and dose frequency for each subject enrolling in the PTG-300-03 study will be based on the last dose and frequency received by the subject in the previous study PTG-300-02 and the subject's response at that dose. Patients dose will be increased in a manner similar to that used on PTG-300-02 study. The maximum PTG-300 dose allowed is 80 mg/week. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04054921
Study type Interventional
Source Protagonist Therapeutics, Inc.
Contact
Status Completed
Phase Phase 2
Start date May 10, 2019
Completion date July 31, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT00560820 - Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload Phase 1
Recruiting NCT05773729 - Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia N/A
Recruiting NCT05864170 - the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia Early Phase 1
Not yet recruiting NCT06440603 - EKLF Gene Expression in β-thalassemia
Recruiting NCT06465550 - A Phase 1 Study of the Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cell in β-thalassemia Major Phase 1
Completed NCT03802201 - Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia Phase 2
Recruiting NCT05745532 - Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients Early Phase 1
Not yet recruiting NCT03358498 - Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox N/A
Recruiting NCT05494333 - Correlation Between Pulmonary Functions and Physical Fitness in Children With β-thalassemia